drugset / Trial / NCT04466345
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).
Timeline
- Start
- 2021-10-06
- Primary completion
- 2024-12-27
- Completion
- 2024-12-27
Publications
- Gill H, Badulescu S, Shah H, Brudner RM, Phan L, Di Vincenzo JD, Tabassum A, Thanarajah SE, Llach CD, Rosenblat JD, McIntyre RS, Mansur RB. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Jul 1;83(7):751-754. doi: 10.1001/jamapsychiatry.2026.0594.
- Badulescu S, Gill H, Shah H, Brudner R, Phan L, Di Vincenzo JD, Tabassum A, Armanyous M, Llach CD, Rosenblat JD, McIntyre RS, Mansur RB. Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Med. 2026 Jan 9;7(1):100916. doi: 10.1016/j.medj.2025.100916. Epub 2025 Nov 10.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 14 mg | Oral |